Loading…
No business profile yet.
Size JINS (3046.T) is a Japan Health Care company (Medical Specialties) with a market value of $865M, the 801st largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥5,840 on 6 Nov 2026.
Performance Over six months the shares fell 11.9%, against -6.0% for the median peer and +1.8% for the Japan market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 14.4% over the last twelve months (peer median +5.5%); the operating margin is 10.3% (peer median 9.6%).
Valuation It trades at 16.6× forward earnings against a peer median of 20.0× (7th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -19 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 20.1 points above its cost of capital (5.0% WACC).
Next results Next results expected around 8 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥111B | ¥111B | ¥97.2B | ¥83.0B | ¥73.3B |
| Revenue growth | — | +14% | +17% | +13% | — |
| Gross profit | ¥85.8B | ¥83.0B | ¥72.9B | ¥61.5B | ¥53.3B |
| EBITDA | ¥15.6B | ¥15.6B | ¥15.0B | ¥10.8B | ¥7.76B |
| Net income | ¥7.80B | ¥7.80B | ¥8.33B | ¥4.67B | ¥1.76B |
| Free cash flow | n/a | ¥7.95B | ¥8.53B | ¥9.10B | ¥3.14B |
| Capital expenditure | n/a | ¥7.86B | ¥5.44B | ¥2.62B | ¥3.59B |
| Total debt | ¥5.71B | ¥5.71B | ¥8.99B | ¥14.1B | ¥13.5B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3046.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.6% | -4.3% | 6th highest of 21 |
| 6-month return | -11.9% | -6.0% | 11th highest of 21 |
| Distance from 52-week high | -37.6% | -30.5% | 8th lowest of 21 |
| Revenue growth (TTM) | +14.4% | +5.5% | 7th highest of 21 |
| Operating margin | 10.3% | 9.6% | 10th highest of 21 |
| Forward P/E | 16.6× | 20.0× | 7th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -7.2% | 6.9% | 2nd least demanding of 16 |
| Growth delivered (Del g) | +11.7% | +11.3% | 8th highest of 16 |
| Hurdle (Req g minus delivered) | -18.9 pp | -2.3 pp | 2nd least demanding of 16 |
| ROIC minus cost of capital | +20.1 pp | +0.9 pp | highest of 21 |
| EV / EBITDA | 8.4× | 11.2× | 5th cheapest of 12 |
| Net debt / EBITDA | -0.4× | -0.1× | 6th least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | n/a | n/a | n/a |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | n/a | n/a | n/a |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 34.7× | n/a | n/a |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 20.7× | 19.6% | +21.4% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 164.7× | 9.2% | -10.2% |